Skip to main content

Table 2 Statistical comparison of clinical features among molecular subtypes.

From: Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization

  Subtype I Subtype II Subtype III Subtype IV Subtype V Subtype VI Fisher's exact test
  N = 37 N = 34 N = 41 N = 81 N = 41 N = 93 p value
Age at diagnosis             
< 50 yr 27 73.0% 16 47.1% 30 73.2% 54 66.7% 22 53.7% 54 58.1%  
>= 50 yr 10 27.0% 18 52.9% 11 26.8% 27 33.3% 19 46.3% 39 41.9% 0.08
T stage              
1 8 21.6% 4 11.8% 10 24.4% 16 19.8% 22 53.7% 41 44.1%  
2 28 75.7% 23 67.6% 20 48.8% 56 69.1% 17 41.5% 44 47.3%  
3 1 2.7% 5 14.7% 7 17.1% 5 6.2% 1 2.4% 7 7.5%  
4 0 0.0% 2 5.9% 4 9.8% 4 4.9% 1 2.4% 1 1.1% 2.00E-05
N stage              
0 20 54.1% 7 20.6% 16 39.0% 31 38.3% 20 48.8% 43 46.2%  
1 10 27.0% 10 29.4% 8 19.5% 25 30.9% 12 29.3% 22 23.7%  
2 4 10.8% 11 32.4% 11 26.8% 14 17.3% 7 17.1% 16 17.2%  
3 3 8.1% 6 17.6% 6 14.6% 11 13.6% 2 4.9% 12 12.9% 0.26
Pos. Lym. Nodes              
0 20 54.1% 6 17.6% 16 39.0% 31 38.3% 20 48.8% 43 46.2%  
1-3 10 27.0% 10 29.4% 8 19.5% 26 32.1% 12 29.3% 22 23.7%  
4-9 4 10.8% 11 32.4% 10 24.4% 13 16.0% 7 17.1% 16 17.2%  
> = 10 3 8.1% 5 14.7% 6 14.6% 9 11.1% 2 4.9% 12 12.9% 0.30
M stage              
0 36 97.3% 33 97.1% 40 97.6% 78 96.3% 41 100.0% 91 97.8%  
1 1 2.7% 1 2.9% 1 2.4% 3 3.7% 0 0.0% 2 2.2% 0.94
TNM Stage              
I 6 16.2% 2 5.9% 10 24.4% 9 11.1% 12 29.3% 28 30.1%  
II 23 62.2% 13 38.2% 11 26.8% 46 56.8% 18 43.9% 36 38.7%  
II 6 16.2% 18 52.9% 19 46.3% 23 28.4% 10 24.4% 27 29.0%  
IV 1 2.7% 1 2.9% 1 2.4% 3 3.7% 0 0.0% 2 2.2% 7.60E-04
Nuclear Grade              
1 1 2.7% 0 0.0% 2 4.9% 2 2.5% 9 22.0% 17 18.3%  
2 3 8.1% 1 2.9% 4 9.8% 11 13.6% 18 43.9% 38 40.9%  
3 30 81.1% 28 82.4% 33 80.5% 62 76.5% 10 24.4% 33 35.5% 0
ER*              
positive 0 (2) 0.0% (5%) 1 (6) 2.9% (20.6%) 10 (13) 24.4% (36%) 70 (66) 86.4% (90.4%) 41 (36) 100.0% (97.2%) 82 (75) 88.2% (91.5%)  
negative 37 (34)) 100.0% (95%) 33 (23) 97.1% (79.4%) 31 (23) 75.6% (64%) 11 (7) 13.6% (9.6%) 0 (1) 0.0% (2.8%) 11 (7) 11.8% (8.5%) 6.31E-51
HER2*              
positive 4 (2) 10.8% (11.8%) 26 (9) 76.5% (81.8%) 18 (16) 43.9% (66.7%) 22 (11) 27.2% (33.3%) 0 (2) 0.0% (13.3%) 5 (7) 5.4% (15.9%)  
negative 33 (17) 89.2% (88.2%) 8 (2) 23.5% (18.2%) 23 (8) 56.1% (33.3%) 59 (22) 72.8% (66.7%) 41 (13) 100.0% (86.7%) 88 (37) 94.6% (84.1%) 9.09E-20
PR*              
positive 19 (9) 51.4% (25%) 14 (11) 41.2% (37.9%) 23 (16) 56.1% (44.4%) 73 (64) 90.1% (87.7%) 41 (34) 100.0% (91.9%) 88 (70) 94.6% (85.4%)  
negative 18 (27) 48.6% (75%) 20 (18) 58.8% (62.1%) 18 (20) 43.9% (55.6%) 8 (9) 9.9% (12.3%) 0 (3) 0.0% (8.1%) 5 (12) 5.4% (14.6%) 2.26E-18
Local Relapse              
No 31 83.8% 27 79.4% 39 95.1% 68 84.0% 34 82.9% 86 92.5%  
Yes 6 16.2% 4 11.8% 1 2.4% 8 9.9% 3 7.3% 6 6.5% 0.29
Regional Relapse              
No 32 86.5% 26 76.5% 37 90.2% 67 82.7% 36 87.8% 84 90.3%  
Yes 2 5.4% 5 14.7% 3 7.3% 6 7.4% 1 2.4% 8 8.6% 0.54
Distant metastasis              
No 31 83.8% 15 44.1% 33 80.5% 50 61.7% 39 95.1% 70 75.3%  
Yes 6 16.2% 16 47.1% 8 19.5% 29 35.8% 2 4.9% 22 23.7% 2.51E-05
  1. *: Numbers in parentheses are results determined by immunohistochemistry. For HER2, 3+ was regarded as positive. P values for ER, HER2 and PR by IHC among all six molecular subtypes were 3 × 10-36, 2 × 10-4 and 1.4 × 10-14, respectively.